Glaxo Revives Sale of Some Antibiotic Treatments

GlaxoSmithKline Plc is rekindling efforts to sell part of its antibiotics business, as the U.K. drugmaker prunes its portfolio to focus more on areas such as cancer, people familiar with the matter said.

Glaxo is working with financial advisers on the potential divestment of its business making antibiotics called cephalosporins, including the Zinnat and Fortum brands, the people said. The portfolio could fetch several hundred million U.S. dollars, according to the people, who asked not to be identified because the deliberations are private.